LOGIN  |  REGISTER

Kairos Pharma (NASDAQ: KAPA) Stock Quote

Last Trade: US$1.37 -0.08 -5.52
Volume: 576,166
5-Day Change: -4.86%
YTD Change: -9.87%
Market Cap: US$17.600M

Latest News From Kairos Pharma

ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. LOS ANGELES / Feb 11, 2025 / Business Wire / Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the... Read More
LOS ANGELES / Feb 06, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, highlighting preclinical data on its glutocorticoid-induced tumor necrosis factor receptor (GITR) agonist, KROS101. In the talk,... Read More
LOS ANGELES / Jan 28, 2025 / Business Wire / Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, being held February 1-5, 2025 in Maui, Hawaii. The talk, titled, “KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor... Read More
LOS ANGELES / Jan 21, 2025 / Business Wire / Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key 2024 milestones and outlook into 2025 in a Letter to Shareholders: Dear Kairos Pharma Shareholders, The management team and Board of Directors of Kairos Pharma Ltd. are pleased to... Read More
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma , (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025 , the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Kairos Pharma's management team will deliver a corporate... Read More
ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. LOS ANGELES / Dec 03, 2024 / Business Wire / Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the... Read More
Compass Therapeutics